JP2024513559A - 新規なＤＡＲＰｉｎベースのＣＤ７０エンゲージャー - Google Patents

新規なＤＡＲＰｉｎベースのＣＤ７０エンゲージャー Download PDF

Info

Publication number
JP2024513559A
JP2024513559A JP2023561342A JP2023561342A JP2024513559A JP 2024513559 A JP2024513559 A JP 2024513559A JP 2023561342 A JP2023561342 A JP 2023561342A JP 2023561342 A JP2023561342 A JP 2023561342A JP 2024513559 A JP2024513559 A JP 2024513559A
Authority
JP
Japan
Prior art keywords
ankyrin repeat
binding
protein
recombinant
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513559A5 (https=
Inventor
クリスティアン ライヒェン
ニーナ レシュケ
ベルント シュレーレス
Original Assignee
モレキュラー パートナーズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー パートナーズ アクチェンゲゼルシャフト filed Critical モレキュラー パートナーズ アクチェンゲゼルシャフト
Publication of JP2024513559A publication Critical patent/JP2024513559A/ja
Publication of JP2024513559A5 publication Critical patent/JP2024513559A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Lock And Its Accessories (AREA)
  • Ignition Installations For Internal Combustion Engines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023561342A 2021-04-09 2022-04-07 新規なＤＡＲＰｉｎベースのＣＤ７０エンゲージャー Pending JP2024513559A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173186P 2021-04-09 2021-04-09
US202163172973P 2021-04-09 2021-04-09
US63/172,973 2021-04-09
US63/173,186 2021-04-09
US202163265181P 2021-12-09 2021-12-09
US63/265,181 2021-12-09
PCT/IB2022/053275 WO2022215032A1 (en) 2021-04-09 2022-04-07 Novel darpin based cd70 engagers

Publications (2)

Publication Number Publication Date
JP2024513559A true JP2024513559A (ja) 2024-03-26
JP2024513559A5 JP2024513559A5 (https=) 2025-04-03

Family

ID=81386901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561342A Pending JP2024513559A (ja) 2021-04-09 2022-04-07 新規なＤＡＲＰｉｎベースのＣＤ７０エンゲージャー

Country Status (9)

Country Link
US (1) US20250074994A1 (https=)
EP (1) EP4319883A1 (https=)
JP (1) JP2024513559A (https=)
KR (1) KR20230169182A (https=)
AU (1) AU2022252985A1 (https=)
BR (1) BR112023020685A2 (https=)
CA (1) CA3214020A1 (https=)
MX (1) MX2023011978A (https=)
WO (1) WO2022215032A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
EP4724460A1 (en) * 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd16a binding proteins and their use
EP4724486A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500879A (ja) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
JP2014501509A (ja) * 2010-11-26 2014-01-23 モレキュラー・パートナーズ・アーゲー 血清アルブミンに結合する設計リピートタンパク質
JP2018511327A (ja) * 2015-04-02 2018-04-26 モレキュラー パートナーズ アクチェンゲゼルシャフト 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン
JP2019512272A (ja) * 2016-03-21 2019-05-16 エルスター セラピューティクス， インコーポレイテッド 多重特異性および多機能性分子ならびにその使用
WO2019200022A1 (en) * 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2020245175A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
WO2020245746A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014317009A1 (en) * 2013-09-05 2016-03-10 Aduro Biotech Holdings, Europe B.V. CD70-binding peptides and method, process and use relating thereto
PE20210708A1 (es) * 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500879A (ja) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
JP2014501509A (ja) * 2010-11-26 2014-01-23 モレキュラー・パートナーズ・アーゲー 血清アルブミンに結合する設計リピートタンパク質
JP2018511327A (ja) * 2015-04-02 2018-04-26 モレキュラー パートナーズ アクチェンゲゼルシャフト 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン
JP2019512272A (ja) * 2016-03-21 2019-05-16 エルスター セラピューティクス， インコーポレイテッド 多重特異性および多機能性分子ならびにその使用
WO2019200022A1 (en) * 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2020245175A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
WO2020245746A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"MOLECULAR PARTNERS: PIONEERING A NEW CLASS OF DRUGS WITH A BROAD PORTFOLIO AND GLOBAL PARTNERSHIPS", [ONLINE], JPN5025000847, 2020, ISSN: 0005791928 *
ANTIBODY THERAPEUTICS, vol. 2, no. 4, JPN5025000846, 2019, pages 79 - 87, ISSN: 0005791929 *
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, vol. 16, no. 1, JPN6026003277, 25 February 2021 (2021-02-25), pages 89 - 96, ISSN: 0005791926 *
J. MOL. BIOL., vol. 382, no. 5, JPN5025000848, 2008, pages 1211 - 1227, ISSN: 0005791927 *
NATURE MEDICINE, vol. 26, no. 9, JPN5025000849, 2020, pages 1459 - 1467, ISSN: 0005791925 *

Also Published As

Publication number Publication date
KR20230169182A (ko) 2023-12-15
MX2023011978A (es) 2023-11-17
CA3214020A1 (en) 2022-10-13
BR112023020685A2 (pt) 2023-12-12
WO2022215032A1 (en) 2022-10-13
AU2022252985A1 (en) 2023-11-16
US20250074994A1 (en) 2025-03-06
EP4319883A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
JP6976335B2 (ja) 組み換え結合タンパク質及びその使用
TWI825086B (zh) Her3抗原結合分子
JP2024513559A (ja) 新規なＤＡＲＰｉｎベースのＣＤ７０エンゲージャー
KR102290592B1 (ko) Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질
US20240150475A1 (en) Novel darpin based cd123 engagers
US20240317852A1 (en) Novel darpin based cd33 engagers
US20220242973A1 (en) Recombinant fap binding proteins and their use
CN107636014A (zh) 抗癌融合多肽
JP2023554379A (ja) 組換えｃｄ３結合タンパク質及びそれらの使用
KR20230155464A (ko) 신규한 DARPin-기반 다중특이성 T-세포 인게이저
WO2024251628A1 (en) Recombinant cd16a binding proteins and their use
CN117242100A (zh) 基于DARPin的新型CD70接合物
CN117255803A (zh) 基于DARPin的新型CD33接合物
CN117177996A (zh) 基于DARPin的新型CD123接合物
CN116802213A (zh) 重组cd3结合蛋白及其用途
CN121263440A (zh) 重组cd2结合蛋白及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260415